These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3243931)

  • 1. Absorption of naproxen controlled-release tablets in fasting and postprandial volunteers.
    Mroszczak E; Yee JP; Bynum L
    J Clin Pharmacol; 1988 Dec; 28(12):1128-31. PubMed ID: 3243931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of a new controlled-release oral naproxen formulation given with and without food.
    Palazzini E; Cristofori M; Babbini M
    Int J Clin Pharmacol Res; 1992; 12(4):179-84. PubMed ID: 1297641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple-dose pharmacokinetics of naproxen from a controlled-release tablet in healthy volunteers.
    Palazzini E; Galli G; Babbini M
    Int J Clin Pharmacol Res; 1990; 10(5):277-84. PubMed ID: 2079385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multiple-dose pharmacokinetic comparison of naproxen as a once-daily controlled-release tablet and a twice-daily conventional tablet.
    Ling TL; Yee JP; Cohen A; Hsiao C; Gonzalez MA; Garg DC; Weidler DJ
    J Clin Pharmacol; 1987 Apr; 27(4):325-9. PubMed ID: 3680592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacokinetic comparison of controlled-release and standard naproxen tablets.
    Ryley NJ; Lingam G
    Curr Med Res Opin; 1988; 11(1):10-5. PubMed ID: 3383611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single- and multiple-dose pharmacokinetic comparison of a sustained-release tablet and conventional tablets of naproxen in healthy volunteers.
    Zhou D; Zhang Q; Lu W; Xia Q; Wei S
    J Clin Pharmacol; 1998 Jul; 38(7):625-9. PubMed ID: 9702847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic profile of extended-release versus immediate-release oral naproxen sodium after single and multiple dosing under fed and fasting conditions: two randomized, open-label trials.
    Laurora I; Wang Y
    Int J Clin Pharmacol Ther; 2016 Oct; 54(10):750-60. PubMed ID: 27639137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady-state pharmacokinetics of enteric-coated naproxen tablets compared with standard naproxen tablets.
    Jung D; Schwartz KE
    Clin Ther; 1994; 16(6):923-9. PubMed ID: 7697688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine.
    Haberer LJ; Walls CM; Lener SE; Taylor DR; McDonald SA
    Headache; 2010 Mar; 50(3):357-73. PubMed ID: 20132340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo evaluation of enteric-coated naproxen tablets using gamma scintigraphy.
    Wilding IR; Hardy JG; Sparrow RA; Davis SS; Daly PB; English JR
    Pharm Res; 1992 Nov; 9(11):1436-41. PubMed ID: 1475230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic evaluation of conventional and controlled-release product of naproxen.
    Palazzini E; Galli G; Babbini M
    Drugs Exp Clin Res; 1990; 16(5):243-7. PubMed ID: 2078990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of naproxen after oral administration of two tablet formulations in healthy volunteers.
    Aarbakke J; Gadeholt G; Høylandskjaer A
    Int J Clin Pharmacol Ther Toxicol; 1983 Jun; 21(6):281-3. PubMed ID: 6885201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the pharmacokinetics of naproxen tablets and suspension in children.
    Wells TG; Mortensen ME; Dietrich A; Walson PD; Blasier D; Kearns GL
    J Clin Pharmacol; 1994 Jan; 34(1):30-3. PubMed ID: 8132849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of a controlled release preparation of naproxen.
    Strocchi E; Ambrosioni E; Palazzini E; Galli G
    Int J Clin Pharmacol Ther Toxicol; 1991 Jul; 29(7):253-6. PubMed ID: 1889910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo studies on HPMC-K-100 M matrices containing naproxen sodium.
    Kumar SM; Chandrasekar MJ; Gopinath R; Srinivasan R; Nanjan MJ; Suresh B
    Drug Deliv; 2007 Mar; 14(3):163-9. PubMed ID: 17454036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro dissolution and in vivo bioavailability of diflunisal/naproxen fixed-dose combination tablets and concomitant administration of diflunisal and naproxen in healthy adult subjects.
    Helmy SA; El Bedaiwy HM
    Drug Res (Stuttg); 2013 Mar; 63(3):150-8. PubMed ID: 23444169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
    Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
    Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of various granulating systems on the bioavailability of naproxen sodium from polymeric matrix tablets.
    Dahl T; Ling T; Yee J; Bormeth A
    J Pharm Sci; 1990 May; 79(5):389-92. PubMed ID: 2352155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.